boehringer glp 1 advances #first #triple #agonist #bi3034701 #obesity #pipeline #glp #gip #npy2 #glucagon #glp #boehringeringelheim #obesity #glp1 #gip #npy2 #cardiometabolic #phase2 #clinicaltrials #drugdevelopment… GLP-1 Agonists: A Comprehensive Overview

Morbidity improvements are generally lower than mortality improvements due to a higher proportion of morbidity incidence (in a critical illness product) being caused by cancers (where the relative risks of incidence by BMI are lower), compared to mortality, with a higher proportion of deaths caused by CVD (where the relative risks by BMI are higher)

Once you pick it, do not put it back into the container

When compared against the average risk score for a diabetic member, diabetic members not taking GLP-1s are riskier than average, while those taking GLP-1s were less risky than averageand, by a wider margin

Lembas has just closed an oversubscribed pre-seed funding round of $3.6m (3m) led by Flora Ventures, which it will use to scale-up production and commercialise its bioactive, coined GLP-1 Edge

Idriss says something as unassuming as a hot yoga class can cause melasma to form